People completing a course of obesity medication, or completing a weight-management programme, need better support to help ...

Nalvee marks a return to the market for a dydrogesterone-only product after an absence of 17 years, and can be used in ...

Don't fall behind. Take a step toward becoming indispensable to your organization by attending our no-cost* LEAN Cell & Gene Boston Summit on Monday, September 22, conveniently planned just one day ...

Pharma 4.0 is no longer a future ambition; it’s the baseline. The ability to operate with real-time data, integrated systems, ...

As excitement builds around GLP-1s and their expanding list of potential indications, the conversation is shifting from hype ...

Grant funding calls are often over-subscribed and success rates can be low. Excellent applications sometimes fail to be ...

The UK has started a 'world-first' gonorrhoea vaccination programme that is designed to prevent thousands of cases and save ...

EVERSANA – which is pharmaphorum's parent company – said that The AI Agency has been set up in collaboration with Google and draws on the tech giant's validated, compliant, and powerful AI, including ...

Vertex already has FDA approval for NaV1.8 inhibitor Journavx (suzetrigine) in acute pain, with late-stage trials on the go ...

The deal with Arrowhead's Visirna Therapeutics subsidiary – which also includes $265 million in milestones tied to potential ...

Moderna has announced a new cost-cutting round as it tries to pare down its annual costs, with a new commitment to cut 10% off its headcount by the end of the year. The target is to reduce its ...

AbbVie could be heading for its second acquisition in the space of a month, as rumours emerge of a $1bn bid for psychiatric drug developer Gilgamesh.